InvestorsHub Logo
Followers 13
Posts 265
Boards Moderated 0
Alias Born 02/17/2021

Re: Itchy palm post# 161140

Friday, 04/23/2021 12:35:29 PM

Friday, April 23, 2021 12:35:29 PM

Post# of 233200
HGEN's Lenzilumab excluded anyone with an O2 level below 94, so it's not a competitor to Leronlimab. Leronlimab that treats the most severe and critical patients, and will likely be used for at risk moderates too once doctors get more familiar with it.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News